Agenzia Italiana del Farmaco
COVID-19 mRNA Vaccines Comirnaty and Spikevax: risk of myocarditis and pericarditis - COVID-19 mRNA Vaccines Comirnaty and Spikevax: risk of myocarditis and pericarditis
COVID-19 mRNA Vaccines Comirnaty and Spikevax: risk of myocarditis and pericarditis
The Italian Medicines Agency would like to inform you of the following:
- Cases of myocarditis and pericarditis have been reported very rarely following vaccination with the COVID-19 mRNA Vaccines Comirnaty and Spikevax.
- The cases primarily occurred within 14 days after vaccination, more often after the second dose and in younger men.
- Available data suggest that the course of myocarditis and pericarditis following vaccination is similar to the course of myocarditis and pericarditis in general.
- Healthcare professionals should be alert to the signs and symptoms of myocarditis and pericarditis.
- Healthcare professionals should advise vaccinated individuals to seek immediate medical attention should they experience chest pain, shortness of breath, or palpitations.
Published on: 19 July 2021
Oggi si celebra il #WorldAutismAwarenessDay.
🔵 L'Agenzia Italiana del Farmaco sostiene la Giornata...
Vai al post →
Jelena Ivanovic, dirigente medico dell’Ufficio Procedure Europee di #HTA di #AIFA, è stata eletta Co...
Vai al post →
Biosimilari: webinar AIFA su terzo Position Paper
La Commissione Scientifica ed Economica (CSE) di ...
Vai al post →
🎙️ Il Presidente #AIFA intervistato da @presadirettarai sulle false terapie a base di cellule stami...
Vai al post →
💛 28 marzo 2026 – Giornata Mondiale dell’Endometriosi 💛
#AIFA si illumina di giallo per accendere...
Vai al post →
🤝🌍 A Roma i lavori dell’EDQM Borderline Products Network Meeting
💬 Il meeting, ospitato da #AIFA...
Vai al post →
